Nathaniel Chin, MD, appeared on numerous Wisconsin news outlets to discuss the recent Food and Drug Administration (FDA) approval of a blood test for Alzheimer’s disease. The accuracy of the blood test was validated using data samples from the Wisconsin Alzheimer’s Disease Research Center (ADRC) and the Wisconsin Registry for Alzheimer’s Prevention (WRAP).
The blood test, known as the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, is for the early detection of amyloid plaques associated with Alzheimer’s disease in adult patients, aged 55 years and older, who are exhibiting signs and symptoms.
“It’s really because of the great Wisconsin participants that we now have something that’s pretty revolutionary,” Chin said to Fox6 News.
Implementation of the blood tests in clinics will take time and training for health care providers, Chin said. Ultimately, Chin described how early and accessible diagnosis could lead to benefits. “People can make lifestyle interventions — that would be exercising, sleep, diet, social engagement” based on these new tests, he said.
Read more about the new FDA-approved blood tests in the article “UW–Madison research helps launch first FDA-cleared blood test for Alzheimer’s” on our website.
In the News
“Wisconsin plays part in FDA-approved Alzheimer’s blood testing” was published online by Fox6 News on May 28, 2025.
“UW-Health, UW-Madison helping with blood test to aid in diagnosing Alzheimer’s disease” was published online by WBAY.com on May 28, 2025.
“Wisconsin Alzheimer’s Institute contributes to FDA-approved blood test diagnosis” was published online by WIFR on May 28, 2025.
“Madison woman hopes to take approved blood test after losing grandmother to Alzheimer’s disease” was published online by WMTV on May 28, 2025.
“UW Health aids FDA approval of Alzheimer’s blood test” was published online by WFRV on May 29, 2025.
